Collegium Pharmaceutical (COLL) Research & Development (2014 - 2022)

Collegium Pharmaceutical has reported Research & Development for 9 years, with the latest figure at $4.0 million in Q1 2022.

• On a quarterly basis, Research & Development rose 35.94% year-over-year to $4.0 million in Q1 2022; TTM through Dec 2022 was $4.0 million, a 57.86% decrease from a year earlier, with the FY2022 full-year figure at $4.0 million, down 57.86% from the prior year.
• Research & Development was $4.0 million for Q1 2022 at Collegium Pharmaceutical, up from $1.6 million in the prior quarter.
• The five-year high for Research & Development was $4.0 million in Q1 2022, with the low at $1.4 million in Q3 2021.
• Average Research & Development over 5 years is $2.5 million, with a median of $2.5 million recorded in 2019.
• The largest YoY upside for Research & Development was 38.87% in 2021 against a maximum downside of 34.91% in 2021.
• Over 5 years, Research & Development stood at $2.2 million in 2018, then advanced by 6.63% to $2.4 million in 2019, then gained by 3.09% to $2.5 million in 2020, then slumped by 34.91% to $1.6 million in 2021, then surged by 147.55% to $4.0 million in 2022.
• The last three Research & Development figures came in at $4.0 million (Q1 2022), $1.6 million (Q4 2021), and $1.4 million (Q3 2021), per Business Quant data.